Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported second-quarter 2026 revenue of $5.2 million, a 35% increase from $3.8 million in the same period of 2025, according to a company press release. For the six months ended June 30, 2026, revenue rose 51% to $10.3 million from $6.8 million a year earlier.

Service revenue drove the quarterly gain, rising to $3.8 million from $1.9 million in the second quarter of 2025, primarily from sleep testing and treatment services at the company's Nevada operations. Product revenue declined to $1.4 million from $1.9 million in the year-ago quarter.

Gross profit for the second quarter was $3.0 million, compared with $2.1 million a year earlier, with gross margin edging up to 57% from 55%. For the six-month period, gross margin was 58% versus 53%.

Operating expenses rose 12% to $7.8 million in the second quarter from $7.0 million a year ago, reflecting higher salaries and wages tied to the SCN acquisition and new treatment center openings. The operating loss was $4.8 million for the quarter, roughly flat with $4.9 million a year earlier, while the six-month operating loss widened to $11.4 million from $8.8 million.

Net loss for the second quarter was $5.5 million, or $0.31 per share, compared with a net loss of $5.0 million, or $0.55 per share, in the second quarter of 2025. For the first half of 2026, net loss totaled $13.3 million versus $8.9 million a year earlier.

At June 30, 2026, cash and cash equivalents were $1.8 million, down from $2.0 million at December 31, 2025. Stockholders' equity deficit widened to $3.8 million from $1.5 million at year-end 2025. Total liabilities stood at $28.1 million against total assets of $24.1 million.

The company noted it has filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.